Premium
TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR‐glycolysis signaling axis
Author(s) -
Li Rongkun,
Weng Li,
Liu Bingyan,
Zhu Lili,
Zhang Xiaoxin,
Tian Guangang,
Hu Lipeng,
Li Qing,
Jiang Shuheng,
Shang Mingyi
Publication year - 2020
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.29433
Subject(s) - pi3k/akt/mtor pathway , protein kinase b , biology , cancer research , glycolysis , cell growth , metastasis , pancreatic cancer , tumor progression , signal transduction , microbiology and biotechnology , cancer , endocrinology , biochemistry , genetics , metabolism
Aberrant expression of the tripartite motif containing 59 (TRIM59) has been reported to participate in the development and progression of various human cancers. However, its expression pattern and cellular roles in pancreatic cancer (PC) remains unclear. In our study, we found that TRIM59 expression was significantly increased in PC tissues and was positively correlated with several malignant behaviors and poor overall survival of PC patients based on bioinformatics analysis and immunohistochemistry staining. Functionally, small interfering RNA–mediated TRIM59 depletion inhibited cell proliferation and migration in vitro, while TRIM59 overexpression promoted cell proliferation and migration in vitro and drove tumor growth and liver metastasis in vivo. Mechanically, TRIM59 was found to enhance glycolysis through activating the PI3K/AKT/mTOR pathway, ultimately contributing to PC progression. Taken together, our results demonstrate that TRIM59 may be a potential predictor for PC and promotes PC progression via the PI3K/AKT/mTOR‐glycolysis signaling pathway, which establishes the rationale for targeting the TRIM59‐related pathways to treat PC.